Anne Tamigniau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Tamigniau has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Chatelain
Laboratoire d’Hématologie, Clinique Universitaire UCL de Mont-Godinne, 5530 Yvoir, Belgium
1 shared publication - Catherine Goffinet
Clinique et Maternité Sainte-Elisabeth, Namur, Belgium
1 shared publication - François Mullier
Department of Laboratory Medicine, CHU UCL Namur, Université Catholique de Louvain, 5530 Yvoir, Belgium
1 shared publication - Jean-Michel Dogné
Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium
1 shared publication - Jonathan Douxfils
Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur, Belgium
1 shared publication
Latest Publications
- Open Access
- 4 November 2014
- Published by Springer Nature in Thrombosis Journal
- Vol. 12 (1) , 24
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux). Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or thromboembolic event during the treatment’s period, in those with acute renal failure, in patients who require urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs.
- 4 November 2014
- Published by Springer Nature in Thrombosis Journal
- Vol. 12 (1) , 24
Open AccessMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as the need for regular coagulation monitoring (VKAs and UFH) or a parenteral route of administration (UFH, LMWHs and fondaparinux). Several non-VKA oral anticoagulants (NOACs) are now widely used in the prevention and treatment of thromboembolic diseases and in stroke prevention in non-valvular atrial fibrillation. Unlike VKAs, NOACs exhibit predictable pharmacokinetics and pharmacodynamics. They are therefore usually given at fixed doses without routine coagulation monitoring. However, in certain patient populations or special clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients experiencing a hemorrhagic or thromboembolic event during the treatment’s period, in those with acute renal failure, in patients who require urgent surgery or in case of an invasive procedure. This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs.